AIV Logo AIV Assistant

 Logo AbbVie Inc. - ABBV 185.49 USD

P/E
65.89
EPS
2.99
Yield
3.44%
P/B
51.33
ROE
54.26
Beta
0.62
Target Price
197.33 USD

185.490 USD

185.490 USD

Daily: +0.00%
Key Metrics

Earnings date: April 24, 2025

P/E: 65.89

EPS: 2.99

Book Value: 3.84

Price to Book: 51.33

Debt/Equity: 1039.99

% Insiders: 0.096%

Growth

Revenue Growth: 0.04%

Earnings Growth: -0.33%

Estimates

Forward P/E: 16.30

Forward EPS: 12.09

Target Mean Price: 197.33

Dividend

Dividend Yield: 3.44%

Annual dividends: 6.38 USD

Ex-Div. Date: April 15, 2025

Payout: 266.46%

5y avg Yield: 3.96%

 Logo About AbbVie Inc. - (ABBV)

Country: United States

Sector: Health Care

Website: http://www.abbvie.com

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Exchange Ticker
GER (Germany) 4AB.DE
DUS (Germany) 4AB.DU
BER (Germany) 4AB.BE
FRA (Germany) 4AB.F
MUN (Germany) 4AB.MU
STU (Germany) 4AB.SG
MEX (Mexico) ABBV.MX
VIE (Austria) ABBV.VI
SAO (Brazil) ABBV34.SA
NYQ (United States) ABBV
Dividend Yield

3.44% (5y avg: 3.96%)

Annual Dividends

6.38 USD

Next ex. div date

April 15, 2025

Payout Ratio

266.46%

Historical Dividends
Year Total Dividends
2026 3.56 USD
2025 6.64 USD
2024 6.20 USD
2023 5.92 USD
2022 5.64 USD
2021 5.20 USD
2020 4.72 USD
2019 4.28 USD
2018 3.59 USD
2017 2.56 USD
2016 2.28 USD
2015 2.02 USD
2014 1.66 USD
2013 1.60 USD

Yearly aggregated dividends

Dividends

AbbVie Inc.
May 15, 2025 Paid
Dividend
1.64 USD
AbbVie Inc.
Feb 14, 2025 Paid
Dividend
1.64 USD
AbbVie Inc.
Nov 15, 2024 Paid
Dividend
1.55 USD
AbbVie Inc.
Aug 15, 2024 Paid
Dividend
1.55 USD

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion